Table 2.
Pharmacological and nonpharmacological reversal of NMBa during COVID-19 time periods.
| Reversal strategy | Total (n=3,602,887) | Baseline period (n=1,644,370) | Before COVID (n=820,078) | Early COVID (n=209,721) | Middle COVID (n=300,791) | Late COVID (n=628,197) |
| Neostigmine, n (%) | 1,411,570 (39.2) | 775,266 (47.1) | 307,727 (37.5) | 67,321 (32.1) | 94,181 (31.3) | 167,075 (26.6) |
| Sugammadex, n (%) | 1,280,618 (35.5) | 417,266 (25.4) | 311,227 (38) | 92,709 (44.3) | 138,148 (45.9) | 321,268 (51.1) |
| No active reversal, n (%) | 910,699 (25.3) | 451,838 (27.5) | 201,124 (24.5) | 49,421 (23.6) | 68,462 (22.8) | 139,854 (22.3) |
aNMB: neuromuscular blockade.